Japan-based biopharmaceutical company Kyowa Hakko Kirin has announced the successful completion and operational status of its expanded manufacturing plant in Shanghai, China. The expansion, which was completed in 15 months, is set to significantly enhance the company’s manufacturing capabilities by doubling its current capacity.
Shanghai Plant’s Strategic Importance
The firm’s China headquarters, situated in the Zhangjiang Hi-tech Park, serves as the company’s sole regional headquarters outside Japan, integrating drug development, manufacturing, warehousing, logistics, and sales. This strategic location underscores Kyowa Hakko Kirin’s commitment to expanding its global footprint and enhancing its service to the Chinese market.
Facility Details and Production Expansion
The 6,300 square meter facility comprises a production area, storage area, and office area. It is primarily utilized for expanding the production of newly introduced biopharmaceutical injections and improving product storage capacity. This expansion is crucial for meeting the growing demand for biopharmaceuticals and ensuring a robust supply chain.
Future Outlook and Impact
The expanded manufacturing capabilities at the Shanghai plant will enable Kyowa Hakko Kirin to accelerate the production and delivery of its biopharmaceutical products, enhancing its competitiveness in the global market. This strategic move is expected to contribute significantly to the company’s growth and its ability to serve patients in China and beyond.-Fineline Info & Tech
